A selective microRNA-based strategy inhibits restenosis while preserving endothelial function.

Area of Science:

• Cardiovascular Research
• Gene Therapy
• Biotechnology

Background:

• Current stent coatings lack specificity, hindering vascular healing and increasing thrombosis risk post-angioplasty.
• Vascular smooth muscle cell (VSMC) proliferation and endothelial cell (EC) dysfunction contribute to restenosis and impaired vascular function.

Purpose of the Study:

• To develop and evaluate a microRNA (miRNA)-based gene therapy strategy to selectively inhibit VSMC proliferation and promote EC function.
• To prevent restenosis and restore vascular health following percutaneous coronary interventions.

Main Methods:

• An adenoviral (Ad) vector (Ad-p27-126TS) was engineered to overexpress p27(Kip1) (p27) with target sequences for EC-specific miR-126-3p.
• In vitro studies assessed EC proliferation, migration, and network formation.
• A rat arterial balloon injury model was used to evaluate the therapeutic efficacy in vivo.

Main Results:

• Ad-p27-126TS treatment in vitro preserved EC proliferation, migration, and network formation.
• In vivo, Ad-p27-126TS significantly reduced restenosis and promoted complete reendothelialization at 2 and 4 weeks post-injury.
• Treated animals showed reduced hypercoagulability and restored acetylcholine-induced vasodilation.

Conclusions:

• A miRNA-based strategy effectively overexpressed p27 in VSMCs while selectively inhibiting it in ECs.
• This approach demonstrates potential for targeted inhibition of vascular restenosis while preserving essential EC functions.
• The study provides a proof-of-principle for a novel therapeutic strategy in cardiovascular interventions.